Methylnissolin-3-O-glucoside
Based on 2 publication(s) in Google Scholar
Methylnissolin-3-O-glucoside is a flavonoid glycoside derivative of Methylnissolin (HY-N2484). Methylnissolin-3-O-glucoside is isolated from plants of the genus Astragalus (Leguminosae). Methylnissolin-3-O-glucoside effectively induces the expression of AKT/Nrf2 and its downstream target genes HO-1 and NQO1. Methylnissolin-3-O-glucoside inhibits TNF-α-induced phosphorylation of MEK and ERK. Methylnissolin-3-O-glucoside exhibits free radical scavenging activity. Methylnissolin-3-O-glucoside inhibits cell proliferation and cell migration. Methylnissolin-3-O-glucoside is used in research on esophageal squamous cell carcinoma.
For research use only. We do not sell to patients.
- Purity : 99.84%
- CAS No.: 94367-42-7
- Formula: C23H26O10
- Molecular Weight:462.45
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Methylnissolin-3-O-glucoside
MoreAll MEK Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
HO-1 |
NQO1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| KYSE-150 cell line | IC50 |
186.44 μM
|
Cytotoxicity against human KYSE150 esophageal carcinoma cells incubated for 24 h.
Cytotoxicity against human KYSE150 esophageal carcinoma cells incubated for 24 h.
|
40356679 |
| KYSE-150 cell line | IC50 |
119.23 μM
|
Cytotoxicity against human KYSE150 esophageal carcinoma cells incubated for 48 h.
Cytotoxicity against human KYSE150 esophageal carcinoma cells incubated for 48 h.
|
40356679 |
In Vitro
Methylnissolin-3-O-glucoside (30 μM; 48 h) inhibits Concanavalin A (HY-P2149)-induced proliferation of primary mouse spleen T cells without cytotoxicity at concentrations up to 100 μM[1].
Methylnissolin-3-O-glucoside (24-48 h) inhibits proliferation of KYSE150 esophageal carcinoma cells with IC50 values of 186.44 μM (24 h) and 119.23 μM (48 h), and shows lower cytotoxicity in normal esophageal epithelial cells[1].
Methylnissolin-3-O-glucoside (1-400 μM; 24 h) has a high safety margin in human glomerular podocytes, with a 24-hour TC50 of 2850 μM[2].
Methylnissolin-3-O-glucoside (1.5-15 μM; 24 h) dose-dependently inhibits TNF-α-induced MEK and ERK phosphorylation in human glomerular podocytes, with prominent inhibition observed at 15 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human glomerular podocytes
-
Concentration:1, 10, 40, 80, 150, 200, 300, 400 μM
-
Incubation Time:24 h
-
Result:Exhibited low cytotoxicity in human glomerular podocytes, with a half-toxic concentration (TC50) of 2850 μM after 24 hours.
-
Cell Line:Human glomerular podocytes
-
Concentration:1.5, 5, 15 μM
-
Incubation Time:24 h (pre-incubation prior to 30 min TNF-α stimulation)
-
Result:Inhibited TNF-α-induced phosphorylation of MEK and ERK in a dose-dependent manner in human glomerular podocytes.
At 15 μM, markedly suppressed MEK and ERK phosphorylation induced by TNF-α.
In Vivo
Methylnissolin-3-O-glucoside (10-60 mg/kg; i.p.; daily; 18 days) effectively inhibits tumor progression in a patient-derived xenograft mouse model of esophageal cancer, with a tolerable safety profile up to 60 mg/kg[1].
Methylnissolin-3-O-glucoside (5-60 mg/kg; i.p.; daily; 7 consecutive days) is well-tolerated in mice at intraperitoneal doses up to 60 mg/kg daily for 7 days, with no detectable organ toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:strain not specified[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; once daily; 3 consecutive days
-
Result:Did not significantly improve liver pathological changes, liver function indicators (ALT, AST), inflammatory factors (IL-6, TNF-α), or the phosphorylation of hepatic P65 and IκB-α in the LPS/D-galactosamine-induced liver injury mouse model.
-
Animal Model:strain not specified (patient-derived xenograft model)[1]
-
Dosage:10 mg/kg (tumor inhibition); 60 mg/kg (safety assessment)
-
Administration:i.p.; daily; 18 days
-
Result:Effectively inhibited tumor progression in the patient-derived xenograft mouse model of esophageal cancer at 10 mg/kg.
Did not cause significant weight loss or organ damage in tumor-bearing mice at 60 mg/kg.
Competitively binds to DDX5 at the K144 site, inhibiting the binding of DDX5 with VAV3 and thereby suppressing esophageal squamous cell carcinoma progression.
-
Animal Model:strain not specified (healthy, normal)[1]
-
Dosage:5-60 mg/kg
-
Administration:i.p.; daily; 7 consecutive days
-
Result:Showed a gradual trend of weight loss at 60 mg/kg, with no statistically significant difference compared to the 0 mg/kg control group.
Revealed no organ-specific lesions in the heart, liver, spleen, lungs, or kidneys across all tested doses via histopathological H&E staining.
Chemical Information
-
CAS No. 94367-42-7
-
Appearance Solid
-
Molecular Weight 462.45
-
Formula C23H26O10
-
Color White to off-white
-
SMILES
COC1=C2O[C@]3([H])[C@](COC4=CC(O[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)CO)=CC=C34)([H])C2=CC=C1OC
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (216.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1624 mL | 10.8120 mL | 21.6240 mL | 54.0599 mL |
| 5 mM | 0.4325 mL | 2.1624 mL | 4.3248 mL | 10.8120 mL | |
| 10 mM | 0.2162 mL | 1.0812 mL | 2.1624 mL | 5.4060 mL | |
| 15 mM | 0.1442 mL | 0.7208 mL | 1.4416 mL | 3.6040 mL | |
| 20 mM | 0.1081 mL | 0.5406 mL | 1.0812 mL | 2.7030 mL | |
| 25 mM | 0.0865 mL | 0.4325 mL | 0.8650 mL | 2.1624 mL | |
| 30 mM | 0.0721 mL | 0.3604 mL | 0.7208 mL | 1.8020 mL | |
| 40 mM | 0.0541 mL | 0.2703 mL | 0.5406 mL | 1.3515 mL | |
| 50 mM | 0.0432 mL | 0.2162 mL | 0.4325 mL | 1.0812 mL | |
| 60 mM | 0.0360 mL | 0.1802 mL | 0.3604 mL | 0.9010 mL | |
| 80 mM | 0.0270 mL | 0.1351 mL | 0.2703 mL | 0.6757 mL | |
| 100 mM | 0.0216 mL | 0.1081 mL | 0.2162 mL | 0.5406 mL |
Methylnissolin-3-O-glucoside Related Classifications
HY-N2473 Related Classifications
Powered by Bioz
Keywords
- Methylnissolin-3-O-glucoside
- 94367-42-7
- Drug Derivative
- Akt
- Keap1-Nrf2
- Heme Oxygenase (HO)
- Quinone Reductase
- MEK
- ERK
- Free Radical Scavengers
- human glomerular podocytes
- iNOS
- IκB/NF-κB
- MEK/ERK
- esophageal squamous cell carcinoma
- KYSE150 esophageal carcinoma cells
- Nrf2
- Astragalus mongholicus
- RAW264.7 macrophages
- COX-2
- Inhibitor
- inhibitor
- inhibit